Drug intelligence / Profile preview

BB710

Development stage: Preclinical
Lead developer: BalinBac Therapeutics
Modality: Small Molecules
Administration: Inhalation, Oral

Overview

**BB710** is a preclinical BalinBac COVID-19 candidate in the proprietary BB-700 Series. It is described as a combination of two or more repurposed, available generic drugs intended to provide multi-mechanistic activity against SARS-CoV-2, including viral entry or attachment, protease, RNA-dependent RNA polymerase, and host metabolic-response pathways. BalinBac has described BB-700 Series candidates as being designed for oral and inhalation-based delivery. ([balinbac.com](https://www.balinbac.com/pipeline))

Beyond the preview

Go deeper on BB710.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB710.

Explore the full profile